EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY 4.0

Efficacy and safety of biologics for hidradenitis suppurativa: A network meta‐analysis of phase III trials

Laura Calabrese iD, Alessandra Cartocci, Pietro Rubegni, Lars E French iD, Benjamin Kendziora iD

Journal of the European Academy of Dermatology and Venereology · 2026-04 · 40 (4) · 637-645

DOI: 10.1111/jdv.20617 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 10.03.2025. Verfasst von Laura Calabrese und 4 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Unit, Department of Medical, Surgical and Neurological Sciences, University of Siena, Siena, Italy. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa, Biological Products. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Munich Clinician Scientist Program (MCSP) of the Ludwig Maximilian University (LMU), European Union (EU)-Next Generation European Union.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Phase III clinical trials are designed to evaluate the therapeutic effect of drugs and their superiority over other treatment methods, but biologics for hidradenitis suppurativa (HS) have not been compared head‐to‐head in phase III studies.

Objectives

To evaluate the relative efficacy and safety of biologics for HS in a network meta‐analysis including available data from phase III trials.

Methods

MEDLINE and Embase were searched for phase III trials investigating the efficacy and/or safety of at least one biologic for moderate‐to‐severe HS. The odds ratios for reaching an HS Clinical Response 50 (HiSCR50) and for the occurrence of adverse events after 12–16 weeks were compared between treatments.

Results

PIONEER I and II (adalimumab 40 mg weekly vs. placebo), SUNSHINE and SUNRISE (secukinumab 300 mg every 2 vs. 4 weeks vs. placebo) as well as BE HEARD I and II (bimekizumab 320 mg every 2 vs. 4 weeks vs. placebo) with 2731 patients were included. Adalimumab weekly was ranked most effective in reaching a HiSCR50 with significant superiority over secukinumab every 2 weeks (OR = 1.74; 95% confidence interval [CI]: 1.11–2.73) and 4 weeks (OR = 1.72; 95% CI: 1.09–2.7) and insignificant superiority over bimekizumab every 2 weeks (OR = 1.23; 95% CI: 0.74–2.06) and 4 weeks (OR = 1.25; 95% CI: 0.73–2.14). Adalimumab showed the fewest adverse events with significant superiority over bimekizumab every 2 weeks (OR = 0.52; 95% CI: 0.32–0.86) and insignificant superiority over bimekizumab every 4 weeks (OR = 0.79; 95% CI: 0.47–1.33) and secukinumab every 2 weeks (OR = 0.69; 95% CI: 0.45–1.07) and 4 weeks (OR = 0.71; 95% CI: 0.46–1.1).

Conclusions

Among currently approved biologic agents for moderate‐to‐severe HS, adalimumab demonstrated the highest efficacy and safety in the first 12–16 weeks of treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hidradenitis SuppurativaBiological ProductsHumansClinical Trials, Phase III as TopicAdalimumabAntibodies, Monoclonal, HumanizedNetwork Meta-Analysis as TopicTreatment Outcome

Substanzen

Biological ProductsAdalimumabAntibodies, Monoclonal, Humanizedsecukinumabbimekizumab

Autor:innen und Institutionen

  • Dermatology Unit, Department of Medical, Surgical and Neurological Sciences, University of Siena, Siena, Italy.
  • Institute of Dermatology, Catholic University of the Sacred Heart, Rome, Italy.
  • Department of Dermatology and Allergy, University Hospital, LMU, Munich, Germany.
  • Department of Dermatology, Thalkirchner Street Hospital, Munich Municipial Hospital Group, Munich, Germany.
  • Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, Florida, USA.
  • Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf, University of Hamburg, Hamburg, Germany.

ORCID-Profile: Laura Calabrese, Lars E French, Benjamin Kendziora

Förderung

  • Munich Clinician Scientist Program (MCSP) of the Ludwig Maximilian University (LMU)
  • European Union (EU)-Next Generation European Union

Zitieren

APA

Calabrese, L., Cartocci, A., Rubegni, P., French, L. E., & Kendziora, B. (2026). Efficacy and safety of biologics for hidradenitis suppurativa: A network meta‐analysis of phase III trials. Journal of the European Academy of Dermatology and Venereology, 40(4), 637-645. https://doi.org/10.1111/jdv.20617

Vancouver

Calabrese L, Cartocci A, Rubegni P, French LE, Kendziora B. Efficacy and safety of biologics for hidradenitis suppurativa: A network meta‐analysis of phase III trials. Journal of the European Academy of Dermatology and Venereology. 2026;40(4):637-645. doi:10.1111/jdv.20617

BibTeX
@article{Calabrese2026,
  author = {Calabrese, Laura and Cartocci, Alessandra and Rubegni, Pietro and French, Lars E and Kendziora, Benjamin},
  title = {Efficacy and safety of biologics for hidradenitis suppurativa: A network meta‐analysis of phase III trials},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2026},
  volume = {40},
  number = {4},
  pages = {637--645},
  doi = {10.1111/jdv.20617}
}
Kostenlos starten →